We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

20 hedge funds and large institutions have $2.14M invested in Cellectar Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.31% more ownership

Funds ownership: 0.04% → 0.35% (+0.31%)

35% less funds holding

Funds holding: 31 → 20 (-11)

41% less capital invested

Capital invested by funds: $3.65M → $2.14M (-$1.51M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

85% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 13

Holders
20
Holders Change
-11
Holders Change %
-35.48%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
6
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$71.9K
2
1WM
1900 Wealth Management
Texas
+$57.5K
3
DCM
Difesa Capital Management
New York
+$43.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$5.03K

Top Sellers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
-$71.9K
2
ACM
AIGH Capital Management
Maryland
-$44.4K
3
Northern Trust
Northern Trust
Illinois
-$39K
4
Citadel Advisors
Citadel Advisors
Florida
-$28K
5
CAM
Cozad Asset Management
Illinois
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$589K – – –
ACM
2
AIGH Capital Management
Maryland
$586K -$44.4K -309 -5%
BlackRock
3
BlackRock
New York
$192K -$2.01K -14 -0.7%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$149K – – –
WVP
5
Worth Venture Partners
New Jersey
$140K -$20K -139 -9%
MS
6
Maven Securities
Jersey
$84K -$71.9K -500 -38%
ACM
7
ACT Capital Management
Pennsylvania
$73K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$59K +$5.03K +35 +6%
State Street
9
State Street
Massachusetts
$53K – – –
Morgan Stanley
10
Morgan Stanley
New York
$50K +$71.9K +500 New
Bank of New York Mellon
11
Bank of New York Mellon
New York
$41K – – –
1WM
12
1900 Wealth Management
Texas
$40K +$57.5K +400 New
Franklin Resources
13
Franklin Resources
California
$35K – – –
DCM
14
Difesa Capital Management
New York
$34K +$43.1K +300 +909%
UBS Group
15
UBS Group
Switzerland
$6K -$11.1K -77 -58%
TRCT
16
Tower Research Capital (TRC)
New York
$5K -$719 -5 -9%
Osaic Holdings
17
Osaic Holdings
Arizona
$2K – – –
IA
18
IFP Advisors
Florida
$1K – – –
US Bancorp
19
US Bancorp
Minnesota
$1K – – –
Northern Trust
20
Northern Trust
Illinois
– -$39K -318 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$28K -230 Closed
CAM
22
Cozad Asset Management
Illinois
– -$23K -187 Closed
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
– -$14K -123 Closed
MWM
24
Modera Wealth Management
New Jersey
– -$8K -67 Closed
VF
25
Virtu Financial
New York
– -$6K -51 Closed
1
2

CLRB Hedge Fund Activity: Q3 2022 in Review

20 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2022, worth a combined $2.14M — down 41% from $3.65M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CLRB and 2 opened new positions — a net loss of 11 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $71.9K. The largest seller was Maven Securities, cutting an estimated $71.9K.

  • 20 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2022, down from 31 in Q2 2022.
  • Funds reported $2.14M of Cellectar Biosciences stock for Q3 2022, down 41% quarter-over-quarter.
  • 2 funds opened new Cellectar Biosciences positions in Q3 2022 and 13 closed out, a net change of -11 holders.
  • The largest Cellectar Biosciences buyer in Q3 2022 was Morgan Stanley, an estimated $71.9K added.
  • The largest Cellectar Biosciences seller in Q3 2022 was Maven Securities, an estimated $71.9K sold.

Based on aggregated 13F filings for Q3 2022.